Saltar al contenido
Merck
Todas las fotos(1)

Documentos

BM0028

Sigma-Aldrich

BMS-536924

≥98% (HPLC)

Sinónimos:

4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, BMS 536924

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C25H26ClN5O3
Número de CAS:
468740-43-4
Peso molecular:
479.96
MDL number:
MFCD20278190
UNSPSC Code:
12352200

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

room temp

SMILES string

CC1=CC(N2CCOCC2)=CC3=C1NC(C4=C(NC[C@@H](O)C5=CC(Cl)=CC=C5)C=CNC4=O)=N3

Biochem/physiol Actions

BMS-536924 is a potent, orally active, ATP-competitive insulin-like growth gactor-1 receptor (IGF1R) inhibitor that shows anticancer activities in preclinical models.

Features and Benefits

BMS-536924 is available through a partnership with Bristol-Myers Squibb (BMS). To learn more and view other BMS compounds, visit sigma.com/BMS.

Legal Information

Sold for research purposes only under agreement from BMS.

Storage Class

13 - Non Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Carly Jade Dool et al.
Endocrine-related cancer, 18(6), 699-709 (2011-09-29)
Epidemiologic and experimental evidence suggest that a subset of breast cancer is insulin responsive, but it is unclear whether safe and effective therapies that target the insulin receptor (IR), which is homologous to oncogenes of the tyrosine kinase class, can
Beate C Litzenburger et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(1), 226-237 (2009-01-02)
This study aimed to test the ability of a new insulin-like growth factor receptor (IGF-IR) tyrosine kinase inhibitor, BMS-536924, to reverse the ability of constitutively active IGF-IR (CD8-IGF-IR) to transform MCF10A cells, and to examine the effect of the inhibitor
Jenny C Potratz et al.
Cancer research, 70(21), 8770-8781 (2010-10-21)
The insulin-like growth factor-1 receptor (IGF1R) is emerging as a promising therapeutic target in human cancers. In the high-risk childhood sarcomas Ewing family tumor and rhabdomyosarcoma, IGF1R-blocking antibodies show impressive antitumor activity in some but not all patients, and acquired

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico